Introduction

The National Neisseria Network (NNN), Australia comprises reference laboratories in each State and Territory that report data on susceptibilities for an agreed group of antimicrobial agents for the Australian Gonococcal Surveillance Programme (AGSP)
* Penicillin resistance includes MIC value of ≥1.0 mg/L, or penicillinase production.
Ceftriaxone
The category of ceftriaxone decreased susceptibility (DS) includes the MIC values 0.06-0.25 mg/L. The breakpoint for ceftriaxone resistance is yet to be determined. In the second quarter of 2018, the proportion of isolates with ceftriaxone decreased susceptibility in Australia was 1.55%, slightly lower than the proportion in the first quarter of 2018, but slightly higher than the annual proportion for 2017. There were no isolates reported in the second quarter of 2018 in Australia with an MIC ≥0.125 mg/L. Of note, there were two isolates from Queensland that exhibited DS to ceftriaxone (MIC = 0.064mg/L) and resistance to azithromycin. One of these was also resistant to penicillin and ciprofloxacin.
The national trend of isolates with ceftriaxone decreased susceptibility (MIC 0.06 and ≥0.125 mg/L) since 2011 is shown in Table 2 . A summary of ceftriaxone DS strains that were penicillin and ciprofloxacin resistant, or isolated from extra genital sites (rectal and pharyngeal) for Quarter 2, 2018 by state or territory, and by sex (male/female) are shown in Table 3 . In quarter 2 2018, most states reported isolates with resistance to azithromycin, with the exception of Tasmania, Australian Capital Territory, and Northern Territory. The states that reported an increase in the proportion of NG isolates with resistance to azithromycin when compared with the first quarter of 2018 were Victoria, and both non-remote and remote Western Australia. All other states and territories reported a decrease in proportion of isolates with azithromycin resistance. There were two isolates, from Queensland, that exhibited resistance to azithromycin and DS to ceftriaxone (MIC = 0.064mg/L). There was one isolate, from New South Wales, that exhibited high level resistance to azithromycin (MIC ≥256 mg/L).
The national trend of azithromycin resistance in isolates since 2012 is shown in 
